Research programme: recombinant human hyaluronidases - Halozyme Therapeutics

Drug Profile

Research programme: recombinant human hyaluronidases - Halozyme Therapeutics

Alternative Names: HTI 201; HTI 401

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Halozyme Therapeutics
  • Class Glycoside hydrolases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Inflammation; Metabolic disorders; Neurological disorders; Wounds

Most Recent Events

  • 14 Jul 2006 A preclinical study has been added to the Cancer pharmacodynamics section
  • 06 Oct 2005 A preclinical study has been added to the Cancer pharmacodynamics section
  • 17 Nov 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top